Halozyme Therapeutics sees strong Q4 2024 growth, driven by ENHANZE platform royalties. Click here to find out why HALO stock ...

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2024 investor letter ...

Halozyme stock is in a consolidation pattern but its chart shows an alternate entry. The biotech name hit two milestones in ...

HC Wainwright reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report published on Thursday,Benzinga reports. Several other equities analysts have also ...

Here is how Brookdale Senior Living (BKD) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take ...

In a report released today, Brendan Smith from TD Cowen maintained a Buy rating on 908 Devices (MASS – Research Report). The company’s shares ...

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price ...

US biotech Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been "unwilling to engage with us to explore a potential combination." Halozyme made ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...